Table 4.
All Participants | CMV IgG Antibody Concentration, IU/mLa |
|||||
≤1.20 | 1.21–10.16 | 10.17–14.55 | 14.56–18.16 | 18.17–150 | ||
Incident frailty (3 years) | ||||||
No. at risk | 482 | 73 | 117 | 101 | 93 | 98 |
No. of events | 80 | 7 | 23 | 14 | 13 | 23 |
Incidence per 1,000 person-years | 60.1 | 29.6 | 69.1 | 52.0 | 51.9 | 91.8 |
95% CI | 48.3, 75.6 | 14.3, 71.9 | 46.4, 107.1 | 30.3, 97.3 | 30.8, 94.6 | 62.0, 141.5 |
Unadjusted hazard ratio | 1.0 | 2.33 | 1.82 | 1.72 | 3.46 | |
95% CI | 0.98, 5.56 | 0.70, 4.70 | 0.67, 4.43 | 1.45, 8.27 | ||
Adjusted hazard ratio*,b | 1.0 | 2.00 | 1.44 | 1.27 | 2.26 | |
95% CI | 0.79, 5.07 | 0.53, 3.95 | 0.46, 3.51 | 0.89, 5.75 | ||
All-cause mortality (5 years) | ||||||
No. at risk | 635 | 92 | 141 | 128 | 130 | 144 |
No. of events | 91 | 7 | 18 | 17 | 14 | 35 |
Incidence per 1,000 person-years | 28.0 | 14.0 | 23.7 | 27.5 | 19.1 | 52.8 |
95% CI | 22.7, 35.0 | 6.7, 34.2 | 14.9, 39.5 | 16.8, 47.9 | 11.3, 34.7 | 37.9, 75.4 |
Unadjusted hazard ratio | 1.0 | 1.68 | 1.97 | 1.36 | 3.81 | |
95% CI | 0.68, 4.16 | 0.78, 4.94 | 0.53, 3.50 | 1.64, 8.83 | ||
Adjusted hazard ratio**,b | 1.0 | 1.95 | 1.87 | 1.29 | 2.79 | |
95% CI | 0.81, 4.68 | 0.75, 4.65 | 0.52, 3.24 | 1.22, 6.40 |
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; IgG, immunoglobulin G.
* P = 0.34; **P < 0.05 (P by likelihood ratio test).
A baseline CMV IgG antibody concentration of >1.20 IU/mL was considered seropositive, reflecting prior CMV infection.
Hazard ratios were derived from Cox proportional hazards models, adjusting for age, race, high school education, coverage by private medical insurance, pack-years of smoking, cardiovascular disease (angina, myocardial infarction, congestive heart failure, peripheral artery disease, or stroke), diabetes mellitus, and plasma interleukin-6 concentration. Comparisons were made with participants whose CMV IgG antibody concentration was ≤1.20 IU/mL.